Quarterly report · Q3
9273.TEDINET S100QQJA
Period2022-07-01 → 2023-03-31
Filed2023-05-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥16.2bn | 2022-07-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥20.4bn | 2021-07-01 → 2022-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥15.0bn | 2021-07-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | ¥3.3bn | 2022-07-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥3.0bn | 2021-07-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥3.2bn | 2022-07-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥3.8bn | 2021-07-01 → 2022-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.1bn | 2021-07-01 → 2022-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥3.2bn | 2022-07-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥3.1bn | 2021-07-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.1bn | 2022-07-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.4bn | 2021-07-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.0bn | 2021-07-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.1bn | 2022-07-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥2.0bn | 2021-07-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥27.5bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥26.2bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥25.4bn | at 2022-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.2bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥7.6bn | at 2022-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥20.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥18.7bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥18.3bn | at 2022-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥9.8bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.1bn | at 2022-06-30 | Cons. | Cash and deposits |
| EPS (basic) | ¥52.48 | 2022-07-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.29 | 2023-01-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.55 | 2021-07-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥50.07 | 2021-07-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥14.8 | 2022-01-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 73.7% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.1% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.1% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2023-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2023-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2023-03-31 | ¥16m |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2022-07-01 → 2023-03-31 | ¥11.5bn |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2022-07-01 → 2023-03-31 | ¥10.2bn |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2022-07-01 → 2023-03-31 | ¥1.4bn |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2022-07-01 → 2023-03-31 | ¥2.0bn |
| jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2022-07-01 → 2023-03-31 | ¥6.0bn |
| jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2022-07-01 → 2023-03-31 | ¥6.0bn |
| jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2022-07-01 → 2023-03-31 | ¥1.2bn |
| —segment total | revenue | 2022-07-01 → 2023-03-31 | ¥17.5bn |
| —segment total | revenue external | 2022-07-01 → 2023-03-31 | ¥16.2bn |
| —segment total | revenue intersegment | 2022-07-01 → 2023-03-31 | ¥1.4bn |
| —segment total | segment profit | 2022-07-01 → 2023-03-31 | ¥3.3bn |
| Reconciling Itemsreconciling | revenue | 2021-07-01 → 2022-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-07-01 → 2022-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | segment profit | 2021-07-01 → 2022-03-31 | ¥38m |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2021-07-01 → 2022-03-31 | ¥10.8bn |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2021-07-01 → 2022-03-31 | ¥9.4bn |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2021-07-01 → 2022-03-31 | ¥1.4bn |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2021-07-01 → 2022-03-31 | ¥1.8bn |
| jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2021-07-01 → 2022-03-31 | ¥5.6bn |
| jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2021-07-01 → 2022-03-31 | ¥5.6bn |
| jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2021-07-01 → 2022-03-31 | ¥1.2bn |
| —segment total | revenue | 2021-07-01 → 2022-03-31 | ¥16.5bn |
| —segment total | revenue external | 2021-07-01 → 2022-03-31 | ¥15.0bn |
| —segment total | revenue intersegment | 2021-07-01 → 2022-03-31 | ¥1.4bn |
| —segment total | segment profit | 2021-07-01 → 2022-03-31 | ¥3.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 361
| Item | Context | Value | Unit |
|---|---|---|---|
| Other noe | Prior1YTDDuration | 1376000 | JPY |
| Other noe | CurrentYTDDuration | 10606000 | JPY |
| Non operating expenses | Prior1YTDDuration | 62604000 | JPY |
| Non operating expenses | CurrentYTDDuration | 88546000 | JPY |
| Ordinary income | Prior1YTDDuration | 3070602000 | JPY |
| Ordinary income | CurrentYTDDuration | 3213891000 | JPY |
| Income before income taxes | Prior1YTDDuration | 3070602000 | JPY |
| Income before income taxes | CurrentYTDDuration | 3213891000 | JPY |
| Income taxes current | Prior1YTDDuration | 1077911000 | JPY |
| Income taxes current | CurrentYTDDuration | 1125972000 | JPY |
| Income taxes deferred | Prior1YTDDuration | 8883000 | JPY |
| Income taxes deferred | CurrentYTDDuration | 8759000 | JPY |
| Income taxes | Prior1YTDDuration | 1086794000 | JPY |
| Income taxes | CurrentYTDDuration | 1134732000 | JPY |
| Profit loss | Prior1YTDDuration | 1983807000 | JPY |
| Profit loss | CurrentYTDDuration | 2079159000 | JPY |
| Profit loss attributable to owners of parent | Prior1YTDDuration | 1983807000 | JPY |
| Profit loss attributable to owners of parent | CurrentYTDDuration | 2079159000 | JPY |
| Profit loss | Prior1YTDDuration | 1983807000 | JPY |
| Profit loss | CurrentYTDDuration | 2079159000 | JPY |
| Valuation difference on available for sale securities net of tax oci | Prior1YTDDuration | -4795000 | JPY |
| Valuation difference on available for sale securities net of tax oci | CurrentYTDDuration | -3951000 | JPY |
| Deferred gains or losses on hedges net of tax oci | Prior1YTDDuration | 17277000 | JPY |
| Deferred gains or losses on hedges net of tax oci | CurrentYTDDuration | -12873000 | JPY |
| Other comprehensive income | Prior1YTDDuration | 12481000 | JPY |
| Other comprehensive income | CurrentYTDDuration | -16824000 | JPY |
| Comprehensive income | Prior1YTDDuration | 1996288000 | JPY |
| Comprehensive income | CurrentYTDDuration | 2062335000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 1996288000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 2062335000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 9413305000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 5623091000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 15036396000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 15036396000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 1423261000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 1423261000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -1423261000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 10836567000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 5623091000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 16459658000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -1423261000 | JPY |
| Net sales | Prior1YTDDuration | 15036396000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 1786306000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 1224920000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 3011226000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | 38337000 | JPY |
| Operating income | Prior1YTDDuration | 3049564000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |